NCT01732094View on ClinicalTrials.gov

Corifollitropin Alfa Followed by hpHMG in a Long GnRH Agonist Protocol for the Treatment of Poor Ovarian Responders

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
InfertilityPoor Ovarian Response
Interventions
DRUG

Triptorelin

Triptorelin 0.1 mg/1 ml solution daily from day 21 of the cycle onwards

DRUG

Corifollitropin alfa 150μg

Corifollitropin alfa 150μg (single dose) 2 or 3 weeks after initiation of triptorelin

DRUG

hpHMG

hpHMG 300IU daily from day 7 following Corifollitropin alfa onwards

Trial Locations (1)

1090

Centre for Reproductive Medicine UZ Brussel, Brussels

All Listed Sponsors
lead

Universitair Ziekenhuis Brussel

OTHER

NCT01732094 - Corifollitropin Alfa Followed by hpHMG in a Long GnRH Agonist Protocol for the Treatment of Poor Ovarian Responders | Biotech Hunter | Biotech Hunter